American Century Companies’s CytomX Therapeutics CTMX Stock Holding History

American Century Companies’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-43,642	Closed	-$363K	–	1627
2019 Q4	$363K	Sell	43,642 -78,930	-64%	-$533K	﹤0.01%	1251
2019 Q3	$905K	Buy	+122,572	New	+$1.21M	﹤0.01%	1034
2018 Q4	–	Sell	-156,248	Closed	-$2.89M	–	1257
2018 Q3	$2.89M	Buy	156,248 +931	+0.6%	+$21.2K	﹤0.01%	963
2018 Q2	$3.55M	Sell	155,317 -49,743	-24%	-$1.27M	﹤0.01%	911
2018 Q1	$5.83M	Sell	205,060 -102,758	-33%	-$2.93M	0.01%	793
2017 Q4	$6.5M	Buy	307,818 +138,019	+81%	+$2.86M	0.01%	790
2017 Q3	$3.08M	Buy	169,799 +110,283	+185%	+$1.72M	﹤0.01%	959
2017 Q2	$922K	Buy	+59,516	New	+$897K	﹤0.01%	1151

Other funds holding CTMX

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

American Century Companies's CTMX Position: Q1 2020 in Review

American Century Companies sold out of CytomX Therapeutics (CTMX) in Q1 2020, closing a stake of 43,642 shares — an estimated $363K sold.

American Century Companies first reported a position in CTMX in Q2 2017 and held it in 8 quarters. The position peaked at $6.5M in Q4 2017. 117 funds tracked by Wall St. Rank hold CTMX as of Q1 2020.

American Century Companies reported no remaining CytomX Therapeutics position as of Q1 2020 after selling out during the quarter.
American Century Companies sold 43,642 CytomX Therapeutics shares in Q1 2020, an estimated $363K.
American Century Companies first reported a position in CytomX Therapeutics in Q2 2017 and held it in 8 quarters.
American Century Companies's CytomX Therapeutics position peaked at $6.5M in Q4 2017.
117 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2020.

Based on American Century Companies's 13F filing for Q1 2020, filed 14 May 2020.